Where is nirsevimab being rolled out for RSV prevention in infants?
Nirsevimab is a shot given to babies to prevent severe respiratory syncytial virus (RSV) infections. A field report specifically describes the rollout of this medicine for infants in New York City 4. Beyond New York, guidelines suggest using this prevention for infants born to mothers with HIV or infants exposed to HIV 6.
What the research says
Reports indicate that nirsevimab administration is being tracked in specific locations like New York City to see how many infants born during the recommended period receive the shot 4. This rollout focuses on protecting infants during their first year of life 6.
The use of nirsevimab extends to specific high-risk populations. Evidence suggests that infants living with HIV or those exposed to HIV should be considered a risk group for nirsevimab prophylaxis 6. Additionally, pregnant women with HIV are advised to receive the RSV vaccine to protect their newborns 6.
While nirsevimab is the newer option, it has shown broadly similar efficacy to the older medicine palivizumab for preventing severe RSV infections in preterm infants 5.
What to ask your doctor
- Is my baby eligible for nirsevimab based on their birth history or health status?
- Does my baby live in an area where nirsevimab is currently being rolled out?
- Are there specific risks for my baby if a parent or sibling has HIV?
- What is the recommended timing for giving nirsevimab to my infant?
This question is drawn from common patient questions about Pediatrics and answered using cited medical research. We do not provide individualized advice.